This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up
by Zacks Equity Research
DNLI maps 2026 goals as it awaits FDA action on tividenofusp alfa, targeting first commercial validation amid multiple late-stage readouts.
biotechnology biotechs medical pharmaceuticals
ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies
by Zacks Equity Research
Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance.
biotechs
FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug
by Zacks Equity Research
Alkermes wins FDA Breakthrough Therapy status for alixorexton in NT1 after Vibrance-1 data shows improvement in wakefulness.
biotechs
OTLK Stock Crashes 67% in a Week: Here's What You Need to Know
by Zacks Equity Research
Outlook Therapeutics stock plunges 67% in a week after the FDA issues a third CRL rejecting its ONS-5010 BLA for wet AMD, again seeking confirmatory data.
biotechnology biotechs medical pharmaceuticals
5 Small Drug Stocks to Buy as Industry Recovery Picks Up
by Kinjel Shah
Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may prove to be good additions to one's portfolio.
biotechs pharmaceuticals
Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline
by Zacks Equity Research
AMGN's $840M buyout of Dark Blue Therapeutics adds a preclinical AML degrader, bolstering its oncology pipeline.
biotechs
ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH
by Zacks Equity Research
Altimmune shares rally 16.52% after the FDA grants Breakthrough Therapy status to pemvidutide for MASH.
biotechs
Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase?
by Zacks Equity Research
CELC shares surge as NDA filing and strong phase III data boost optimism around gedatolisib's potential.
biotechs
ANIP Up 21% in 6 Months: Is It Worth Investing in the Stock Now?
by Sundeep Ganoria
ANI Pharmaceuticals' shares are up 21% in six months as strong 2025 results, repeated earnings beats and higher guidance highlight momentum in rare diseases.
biotechs medical
ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study
by Zacks Equity Research
Zenas BioPharma tanks nearly 52% despite positive INDIGO study data where obexelimab cut IgG4-RD flare risk by 56% and met all key endpoints.
biotechs